Cargando…

Targeting BCL2 Family in Human Myeloid Dendritic Cells: A Challenge to Cure Diseases with Chronic Inflammations Associated with Bone Loss

Rheumatoid arthritis (RA) and Langerhans cell histiocytosis (LCH) are common and rare diseases, respectively. They associate myeloid cell recruitment and survival in inflammatory conditions with tissue destruction and bone resorption. Manipulating dendritic cell (DC), and, especially, regulating the...

Descripción completa

Detalles Bibliográficos
Autores principales: Olsson Åkefeldt, Selma, Ismail, Mohamad Bachar, Valentin, Hélène, Aricò, Maurizio, Henter, Jan-Inge, Delprat, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674653/
https://www.ncbi.nlm.nih.gov/pubmed/23762095
http://dx.doi.org/10.1155/2013/701305
_version_ 1782272399746531328
author Olsson Åkefeldt, Selma
Ismail, Mohamad Bachar
Valentin, Hélène
Aricò, Maurizio
Henter, Jan-Inge
Delprat, Christine
author_facet Olsson Åkefeldt, Selma
Ismail, Mohamad Bachar
Valentin, Hélène
Aricò, Maurizio
Henter, Jan-Inge
Delprat, Christine
author_sort Olsson Åkefeldt, Selma
collection PubMed
description Rheumatoid arthritis (RA) and Langerhans cell histiocytosis (LCH) are common and rare diseases, respectively. They associate myeloid cell recruitment and survival in inflammatory conditions with tissue destruction and bone resorption. Manipulating dendritic cell (DC), and, especially, regulating their half-life and fusion, is a challenge. Indeed, these myeloid cells display pathogenic roles in both diseases and may be an important source of precursors for differentiation of osteoclasts, the bone-resorbing multinucleated giant cells. We have recently documented that the proinflammatory cytokine IL-17A regulates long-term survival of DC by inducing BCL2A1 expression, in addition to the constitutive MCL1 expression. We summarize bibliography of the BCL2 family members and their therapeutic targeting, with a special emphasis on MCL1 and BCL2A1, discussing their potential impact on RA and LCH. Our recent knowledge in the survival pathway, which is activated to perform DC fusion in the presence of IL-17A, suggests that targeting MCL1 and BCL2A1 in infiltrating DC may affect the clinical outcomes in RA and LCH. The development of new therapies, interfering with MCL1 and BCL2A1 expression, to target long-term surviving inflammatory DC should be translated into preclinical studies with the aim to increase the well-being of patients with RA and LCH.
format Online
Article
Text
id pubmed-3674653
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-36746532013-06-12 Targeting BCL2 Family in Human Myeloid Dendritic Cells: A Challenge to Cure Diseases with Chronic Inflammations Associated with Bone Loss Olsson Åkefeldt, Selma Ismail, Mohamad Bachar Valentin, Hélène Aricò, Maurizio Henter, Jan-Inge Delprat, Christine Clin Dev Immunol Review Article Rheumatoid arthritis (RA) and Langerhans cell histiocytosis (LCH) are common and rare diseases, respectively. They associate myeloid cell recruitment and survival in inflammatory conditions with tissue destruction and bone resorption. Manipulating dendritic cell (DC), and, especially, regulating their half-life and fusion, is a challenge. Indeed, these myeloid cells display pathogenic roles in both diseases and may be an important source of precursors for differentiation of osteoclasts, the bone-resorbing multinucleated giant cells. We have recently documented that the proinflammatory cytokine IL-17A regulates long-term survival of DC by inducing BCL2A1 expression, in addition to the constitutive MCL1 expression. We summarize bibliography of the BCL2 family members and their therapeutic targeting, with a special emphasis on MCL1 and BCL2A1, discussing their potential impact on RA and LCH. Our recent knowledge in the survival pathway, which is activated to perform DC fusion in the presence of IL-17A, suggests that targeting MCL1 and BCL2A1 in infiltrating DC may affect the clinical outcomes in RA and LCH. The development of new therapies, interfering with MCL1 and BCL2A1 expression, to target long-term surviving inflammatory DC should be translated into preclinical studies with the aim to increase the well-being of patients with RA and LCH. Hindawi Publishing Corporation 2013 2013-05-22 /pmc/articles/PMC3674653/ /pubmed/23762095 http://dx.doi.org/10.1155/2013/701305 Text en Copyright © 2013 Selma Olsson Åkefeldt et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Olsson Åkefeldt, Selma
Ismail, Mohamad Bachar
Valentin, Hélène
Aricò, Maurizio
Henter, Jan-Inge
Delprat, Christine
Targeting BCL2 Family in Human Myeloid Dendritic Cells: A Challenge to Cure Diseases with Chronic Inflammations Associated with Bone Loss
title Targeting BCL2 Family in Human Myeloid Dendritic Cells: A Challenge to Cure Diseases with Chronic Inflammations Associated with Bone Loss
title_full Targeting BCL2 Family in Human Myeloid Dendritic Cells: A Challenge to Cure Diseases with Chronic Inflammations Associated with Bone Loss
title_fullStr Targeting BCL2 Family in Human Myeloid Dendritic Cells: A Challenge to Cure Diseases with Chronic Inflammations Associated with Bone Loss
title_full_unstemmed Targeting BCL2 Family in Human Myeloid Dendritic Cells: A Challenge to Cure Diseases with Chronic Inflammations Associated with Bone Loss
title_short Targeting BCL2 Family in Human Myeloid Dendritic Cells: A Challenge to Cure Diseases with Chronic Inflammations Associated with Bone Loss
title_sort targeting bcl2 family in human myeloid dendritic cells: a challenge to cure diseases with chronic inflammations associated with bone loss
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674653/
https://www.ncbi.nlm.nih.gov/pubmed/23762095
http://dx.doi.org/10.1155/2013/701305
work_keys_str_mv AT olssonakefeldtselma targetingbcl2familyinhumanmyeloiddendriticcellsachallengetocurediseaseswithchronicinflammationsassociatedwithboneloss
AT ismailmohamadbachar targetingbcl2familyinhumanmyeloiddendriticcellsachallengetocurediseaseswithchronicinflammationsassociatedwithboneloss
AT valentinhelene targetingbcl2familyinhumanmyeloiddendriticcellsachallengetocurediseaseswithchronicinflammationsassociatedwithboneloss
AT aricomaurizio targetingbcl2familyinhumanmyeloiddendriticcellsachallengetocurediseaseswithchronicinflammationsassociatedwithboneloss
AT henterjaninge targetingbcl2familyinhumanmyeloiddendriticcellsachallengetocurediseaseswithchronicinflammationsassociatedwithboneloss
AT delpratchristine targetingbcl2familyinhumanmyeloiddendriticcellsachallengetocurediseaseswithchronicinflammationsassociatedwithboneloss